Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients

References

• Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity – the experience of the Lombardy dialysis registry. Nephrol Dial Transplant. 1998;13:1642–1644
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in hemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–132
   PubMed Web of Science ®Google Scholar
• Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant. 2001;16:224–227
   PubMed Web of Science ®Google Scholar
• Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents—what do we know and what needs to be clarified? Nephrol Dial Transplant. 2005;20(Suppl 8):viii2–viii7
   PubMedGoogle Scholar
• Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17(Suppl 11):39–43
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
   PubMed Web of Science ®Google Scholar
• Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63–72
   PubMed Web of Science ®Google Scholar
• Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis. 2001;38:1408–1413
   PubMed Web of Science ®Google Scholar
• Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004;65:2371–2379
   PubMed Web of Science ®Google Scholar
• Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial. 2004;17:449–454
   PubMed Web of Science ®Google Scholar
• Cuevas X, García F, Martín-Malo A, et al. Risk factors associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: two-year results from the ANSWER Study. Blood Purif. 2011;33:21–29
   PubMedGoogle Scholar
• Yen TH, Lin JL, Lin-Tan DT, Hsu CW. Association between body mass and mortality in maintenance hemodialysis patients. Ther Apher Dial. 2010;14:400–408
   PubMedGoogle Scholar
• Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep. 2012;14:152–159
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543–554
   PubMed Web of Science ®Google Scholar
• Kalaitzidis RG, Siamopoulos KC. The role of obesity in kidney disease: recent findings and potential mechanisms. Int Urol Nephrol. 2011;43:771–784
   PubMedGoogle Scholar
• Hillman RS, Ault KA. Clinical approach to anemia. In: Hillman RS, Ault KA. eds. Hematology in Clinical Practice. 3rd edn. New York: McGraw-Hill; 2002:12–26
   Google Scholar
• Strippoli GF, Manno C, Schena FP, Craig JC. Hemoglobin and hematocrit targets for the anaemia of chronic renal disease (Cochrane review). Cochrane Database Syst Rev. 2003;1:CD003967
   Google Scholar
• Costa E, Lima M, Alves JM, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28:268–275
   PubMed Web of Science ®Google Scholar
• Costa E, Pereira BJ, Rocha-Pereira P, et al. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol. 2008;28:677–683
   PubMed Web of Science ®Google Scholar
• Bazeley J, Bieber B, Li Y, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2452–2456
   PubMed Web of Science ®Google Scholar
• Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin Biochem. 2011;44:1189–1198
   PubMed Web of Science ®Google Scholar
• Jacober ML, Mamoni RL, Lima CS, Dos Anjos BL, Grotto HZ. Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia. Med Oncol. 2007;24:323–329
   PubMed Web of Science ®Google Scholar
• Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA. 2001;98:8160–8162
   PubMed Web of Science ®Google Scholar
• Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression trough STAT3. Blood. 2006;108:3204–3209
   PubMed Web of Science ®Google Scholar
• Dallalio G, Fleury T, Means RT. Serum hepcidin in clinical specimens. Br J Hematol. 2003;122:996–1000
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Gehrke SG, Janetzko A, et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary hemochromatosis, chronic renal insufficiency, and renal anemia. Gut. 2004;53:735–743
   PubMed Web of Science ®Google Scholar
• Hsu SP, Ching CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif. 2006;24:311–316
   PubMedGoogle Scholar
• Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–920
   PubMed Web of Science ®Google Scholar
• Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326–330
   PubMed Web of Science ®Google Scholar
• Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55:667–674
   PubMed Web of Science ®Google Scholar
• Nascimento H, Silva L, Lourenço P, et al. Lipid profile in Portuguese obese children and adolescents: interaction of apolipoprotein E polymorphism with adiponectin levels. Arch Pediatr Adolesc Med. 2009;163:1030–1036
   PubMedGoogle Scholar
• Nascimento H, Costa E, Rocha-Pereira P, et al. Cardiovascular risk factors in portuguese obese children and adolescents: impact of small reductions in body mass index imposed by lifestyle modifications. Open Biochem J. 2012;6:43–50
   PubMedGoogle Scholar
• Adamczak M, Chudek J, Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial. 2009;22:391–395
   PubMedGoogle Scholar
• Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009;22:70–77
   PubMed Web of Science ®Google Scholar
• Tussing-Humphreys LM, Nemeth E, Fantuzzi G, et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity. 2010;18:1449–1456
   PubMed Web of Science ®Google Scholar